GLP-1 Weight-Loss Drug Use Surges in Children Under 12: What You Need to Know
A new report shows a 300-fold increase in GLP-1 drug prescriptions for U.S. children under 12, raising questions about approved uses.
A recent report from AnewZ has highlighted a significant trend: the use of GLP-1 weight-loss drugs among U.S. children under 12 has surged 300-fold AnewZ via Google News. This is a striking increase, especially given the current FDA approvals for these medications.
What Are GLP-1 Medications?
GLP-1 stands for glucagon-like peptide-1. These medications, like semaglutide (brand names Wegovy, Ozempic) and tirzepatide (brand name Zepbound), work by mimicking a natural hormone in your body that helps regulate blood sugar and appetite. According to MedlinePlus, treatments for diabetes often include medicines, and these drugs were initially developed to help manage type 2 diabetes Diabetes Medicines. Some have since been approved for chronic weight management.
Who Are They Approved For?
The FDA has specific guidelines for who can take these powerful medications. For example, the FDA's label for Wegovy (semaglutide), which is indicated for chronic weight management, specifies its use for adults and pediatric patients aged 12 years and older with obesity FDA via DailyMed.
Zepbound (tirzepatide), another GLP-1 receptor agonist approved for weight management, is indicated for adults with obesity or overweight with at least one weight-related comorbid condition FDA via DailyMed. Ozempic (semaglutide) is indicated for adults with type 2 diabetes to improve glycemic control and reduce cardiovascular risk FDA via DailyMed.
This means that for weight loss, the approved age for semaglutide (Wegovy) is 12 and up, and for tirzepatide (Zepbound), it's adults only. The reported surge in use among children under 12 for weight loss would therefore be considered off-label use.
Why the Increase in Younger Children?
The AnewZ report doesn't detail the reasons behind this surge, but it highlights a growing conversation around childhood obesity and the search for effective interventions. While GLP-1s have shown significant results in older populations, their use in very young children is not within the current FDA-approved guidelines for weight management.
When a medication is used off-label, it means a doctor is prescribing it for a condition or age group not specifically listed on the FDA-approved label. This is a common practice in medicine, but it relies on a prescriber's clinical judgment and a thorough discussion of potential benefits and risks.
Important Considerations
All medications carry potential side effects. According to the FDA's label for Wegovy, common adverse reactions in adults and pediatric patients aged 12 and older include nausea, diarrhea, vomiting, constipation, and abdominal pain FDA via DailyMed. Other serious warnings include the risk of thyroid C-cell tumors, acute pancreatitis, and gallbladder disease. The long-term effects of GLP-1 medications on the developing bodies of children under 12 are not as well-studied as in older age groups.
What This Means For You
- Understand FDA Approvals: Be aware that common GLP-1 weight-loss medications like Wegovy are currently approved for chronic weight management in individuals aged 12 and older, and Zepbound for adults.
- Discuss With Your Prescriber: If you are considering any medication for weight management, especially for a child, have an in-depth conversation with a qualified healthcare provider about the potential benefits, risks, and any off-label considerations.
- Focus on Comprehensive Care: Medication is one tool in weight management. A holistic approach that includes diet, physical activity, and behavioral support is crucial, especially for children.
Not medical advice. Talk to your prescriber about your situation.
